Figure 3
From: A preliminary study on efficacy of rupatadine for the treatment of acute dengue infection
Changes in clinical and laboratory parameters in patients on 40 mg of rupatadine and placebo. (a) Height of the pleural effusion was measured by daily ultrasound scan and expressed in time (days) since onset of symptoms. Dotted line represents patients receiving rupatadine (40 mg daily, n = 66), and solid lines represent those receiving placebo (n = 67). (b) Haematocrit was measured daily and expressed as percentage change from the baseline value at presentation. Serum aspartate transaminase levels (c), alanine transaminase (d), and blood platelet counts were measured (e). The number of patients included for the analysis for each parameter, each day is indicated in the x-axis below each day (rupatadine/placebo). The bars represent median and the interquartile range *P < 0.05.
